[The concept of innovative drugs has been active repeatedly, CanSino has hit the 20cm daily limit] On September 30, the concept of innovative drugs has been active again and again, with CanSino hitting the 20cm daily limit, and Technomax, Harbin Pharmaceutical Co., Ltd., JianKai Technology, Yahong Pharmaceutical, Watson Biotech, etc. quickly followed suit. On the news, on September 29, Summit announced that AstraZeneca will make a strategic equity investment of US$2 billion in the company and will lead the clinical research of Ivosi combined with AstraZeneca’s Sonesitatug Vedotin (Sone-Ve, CLDN18.2 ADC) for the treatment of various gastrointestinal tumors. At the same time, the two parties plan to further promote the clinical exploration of combination therapy between Ivosi and AstraZeneca’s series of ADC drugs and other anti-tumor drugs.